Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
With the average number of 6-7 authors per (clinical) publication and an increasing trend for multi-authored articles there are now plenty of opportunities for industrious clinicians to publish. Here are just a few examples of super-achievers from the Infectious Disease space: By simple math, we can see that these gentlemen Continue reading PUBLICATION OVERACHIEVERS
GSK’s pipeline in anti-infectives is impressive. It comprises drugs for bacterial, mycobacterial, fungal, viral infections, and for malaria; in addition, they have a number of vaccines in development. Several antibiotics are listed on their website targeting UTI pathogens, and one of them was just approved, namely gepotidacin / Blujepa, a Continue reading BLUJEPA / Gepotidacin APPROVED FOR UNCOMPLICATED UTI – 1
Study Design in ABSSSI – A Statistician’s Delight The design of the O’Riordan ABSSI study [1] deserves comment. This was a double-blind study of 2 lower dose arms (Part 1) with an add-on open-label (Part 2) high-dose arm. The pimary endpoint was a non-standard composite efficacy and safety endpoint that Continue reading Gepotidacin ABSSSI – How to Fail Adaptively,